钠-葡萄糖共转运体2抑制剂在肾脏病中的研究进展及在常染色体显性多囊肾病中的潜在作用

SGLT2 inhibitors in kidney disease and their potential role in ADPKD

钠-葡萄糖共转运体2抑制剂是一类通过抑制近端肾小管葡萄糖重吸收发挥作用的新型降糖药。在过去的几年中,有越来越多的研究表明钠-葡萄糖共转运体2抑制剂除了能够有效降低血糖外,对肾脏还有额外的保护作用。常染色体显性多囊肾病是一种最常见的单基因遗传性肾脏疾病。该病呈进行性进展,最终导致终末期肾病,会显著增加社会经济负担和疾病的致死率。目前临床上尚缺乏针对多囊肾病的特异性治疗药物。本文就钠-葡萄糖共转运体2抑制剂在肾脏疾病中的研究进展及在常染色体显性多囊肾病中的潜在作用进行综述。

Sodium-glucose cotransporter 2 inhibitors(SGLT2 inhibitors) are a new type of hypoglycemic drug that inhibit glucose reabsorption in proximal renal tubules. Except for blood glucose reduction, SGLT2 inhibitors play an important role in kidney protection. Autosomal dominant polycystic kidney disease(ADPKD) is the most common single-gene hereditary kidney disease that develops rapidly and leads to end-stage renal disease, which can significantly increase the socio-economic burden and mortality. At present, there is no effective treatment for ADPKD. This review aims to introduce the research advancement of SGLT2 inhibitors in kidney disease and the potential role in ADPKD.